Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer's Treatment
The DOI matches its Crossref record; 8 of the 9 references it cites were found in a registry or an index.
Abstract
Promising early-stage trial results provide hope that a therapy for Alzheimer's disease may become available that can prevent progression to full-blown dementia. But an important challenge will arise: A substantial backlog of existing cases with early-stage disease would have to be screened, diagnosed, and then potentially treated. This report assesses the preparedness of the U.S. health care system to handle the potential caseload.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Anticipating the development and approval of aducanumab (or a similar therapy), a 2017 simulation by RAND Corporation researchers found that”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [655]
In the citing paper
“As with the earlier discussion on barriers to diagnosis, this simulation highlights how workforce shortages can directly impact individuals' health outcomes and underscores the need to expand the workforce to meet existing and future demand.”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [655]
In the citing paper
“The researchers projected an average wait time of 18.6 months between diagnosis and treatment once the new drug was approved.”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [655]
In the citing paper
“Capacity constraints -such as a limited number of qualified providers and facilities -could severely restrict access to new treatments.655,806”
From 2023 Alzheimer's disease facts and figures (2023) · cites this paper as [655]
In the citing paper
“modeling by the RAND Corporation in 2017 showed that with an anti‐amyloid therapy for people in the MCI and early dementia stages of the disease, approximately 2.1 million individuals with MCI due to Alzheimer's disease would develop Alzheimer's dementia between 2020 and 2040 while on waiting lists for treatment.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [972]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Hebert, L. E., Weuve, J., Scherr, P. A., & Evans, D. A. (2013) · Neurology · doi:10.1212/wnl.0b013e31828726f5 · Cited by 2,642
Sachdev, P. S., Lipnicki, D. M., Kochan, N. A., Crawford, J. D., Thalamuthu, A., Andrews, G., Brayne, C., Matthews, F. E., Stephan, B. C. M., Lipton, R. B., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0142388 · Cited by 380
Current Research Therapeutic Strategies for Alzheimer’s Disease Treatment
Folch, J., Petrov, D., Ettcheto, M., Abad, S., Sánchez-López, E., García, M. L., Olloquequi, J., Beas-Zarate, C., Auladell, C., & Camins, A. (2016) · Neural Plasticity · doi:10.1155/2016/8501693 · Cited by 270 · cited 1×
“While the exact pathobiology is not fully understood, those plaques are associated with degeneration of neurons, leading to dementia (Folch et al., 2016).”
BackgroundEconomic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches
Buck, A. K., Herrmann, K., Stargardt, T., Dechow, T., Krause, B. J., & Schreyogg, J. (2010) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.108.059584 · Cited by 107
Supply and demand analysis of the current and future US neurology workforce
Racette, B. A., & Holtzman, D. M. (2014) · Neurology · doi:10.1212/wnl.0000000000000509 · Cited by 28
Outcomes of Treatment for Hepatitis C Virus Infection by Primary Care Providers
Harnois, D. M. (2011) · Yearbook of Gastroenterology · doi:10.1016/j.ygas.2011.07.083 · Cited by 19
(2017) · Springer Publishing Company eBooks · doi:10.1891/9780826150349.0017 · Cited by 14
The Workforce Task Force Report: Clinical implications for neurology
Hodgson, T. S., & Lukas, R. V. (2014) · Neurology · doi:10.1212/wnl.0000000000000161 · Cited by 9
Cited by
2023 Alzheimer's disease facts and figures
(2023) · Alzheimer's & Dementia · doi:10.1002/alz.13016 · Cited by 3,212
2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
2022 Alzheimer's disease facts and figures
(2022) · Alzheimer's & Dementia · doi:10.1002/alz.12638 · Cited by 2,341
2021 Alzheimer's disease facts and figures
(2021) · Alzheimer's & Dementia · doi:10.1002/alz.12328 · Cited by 2,201
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
“health care system to care for people with Alzheimer’s disease or related dementias in the upcoming decades [401].”
Global estimates on the number of persons across the Alzheimer's disease continuum
Gustavsson, A., Norton, N., Fast, T., Frölich, L., Georges, J., Holzapfel, D., Kirabali, T., Krolak‐Salmon, P., Rossini, P. M., Ferretti, M. T., et al. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12694 · Cited by 895
Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021
Porsteinsson, A. P., Isaacson, R. S., Knox, S., Sabbagh, M. N., & Rubino, I. (2021) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2021.23 · Cited by 744
“…this will result in an increase in patients requiring diagnosis, increasing the demand for specialists to evaluate and diagnose, the need for amyloid confirmation, and wait times for patients, which will collectively put further pressure on an already-stretched healthcare infrastructure (25).”
Influential2025 Alzheimer's disease facts and figures
(2025) · Alzheimer's & Dementia · doi:10.1002/alz.70235 · Cited by 474
Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies
Zetterberg, H., & Bendlin, B. B. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0721-9 · Cited by 377
Developing the ATX(N) classification for use across the Alzheimer disease continuum
Hampel, H., Cummings, J., Blennow, K., Gao, P., Jack, C. R., & Vergallo, A. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00520-w · Cited by 327
Liss, J. L., Seleri Assunção, S., Cummings, J., Atri, A., Geldmacher, D. S., Candela, S. F., Devanand, D. P., Fillit, H. M., Susman, J., Mintzer, J., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13244 · Cited by 312
Causes and Patterns of Dementia: An Update in the Era of Redefining Alzheimer's Disease
James, B. D., & Bennett, D. A. (2019) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-040218-043758 · Cited by 199
Designing the next-generation clinical care pathway for Alzheimer’s disease
Hampel, H., Au, R., Mattke, S., van der Flier, W. M., Aisen, P., Apostolova, L., Chen, C., Cho, M., De Santi, S., Gao, P., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00269-x · Cited by 191
Self-citationAducanumab: evidence from clinical trial data and controversies
Tampi, R. R., Forester, B. P., & Agronin, M. (2021) · Drugs in Context · doi:10.7573/dic.2021-7-3 · Cited by 190
Veitch, D. P., Weiner, M. W., Aisen, P. S., Beckett, L. A., DeCarli, C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Landau, S. M., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12422 · Cited by 184
Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging
Pittock, R. R., Aakre, J. A., Castillo, A. M., Ramanan, V. K., Kremers, W. K., Jack, C. R., Vemuri, P., Lowe, V. J., Knopman, D. S., Petersen, R. C., et al. (2023) · Neurology · doi:10.1212/wnl.0000000000207770 · Cited by 151
“39 In our study, although the sample would not represent patients visiting a memory clinic, 1,136 patients (mainly with MCI) needed assessment and 32% met leca-nemab inclusion criteria and would continue with further assessment (e.g., exclusion criteria and PET scan, as needed).”
BackgroundMethodAlzheimer disease blood biomarkers: considerations for population-level use
Mielke, M. M., & Fowler, N. R. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00989-1 · Cited by 148
“In addition, CSF and PET biomarkers often need to be requested by dementia specialists, such as neurologists, psychiatrists or geriatricians, who are in short supply worldwide, resulting in long waiting times 7,8 .”
Hlavka, J., Mattke, S., & Liu, J. (2018) · RAND Corporation eBooks · doi:10.7249/rr2503 · Cited by 133
Self-citationGrassi, M., Rouleaux, N., Caldirola, D., Loewenstein, D., Schruers, K. R. J., Perna, G., Dumontier, M., & Initiative, A. D. N. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00756 · Cited by 145
Ginkgo biloba in the Aging Process: A Narrative Review
Barbalho, S. M., Direito, R., Laurindo, L. F., Marton, L. T., Guiguer, É. L., Goulart, R. D. Á., Tofano, R. J., de Carvalho, A. C. A., Flato, U. A. P., Tofano, V. A. C., et al. (2022) · Antioxidants · doi:10.3390/antiox11030525 · Cited by 120
Alfano, C. M., Mayer, D. K., Bhatia, S., Maher, J., Scott, J. M., Nekhlyudov, L., Merrill, J. K., & Henderson, T. O. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21558 · Cited by 99
Mullane, K., & Williams, M. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.113945 · Cited by 105
Perspectives and challenges in patient stratification in Alzheimer’s disease
Abdelnour, C., Agosta, F., Bozzali, M., Fougère, B., Iwata, A., Nilforooshan, R., Takada, L. T., Viñuela, F., & Traber, M. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01055-y · Cited by 108
Mullane, K., & Williams, M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.09.026 · Cited by 98
Hampel, H., Shaw, L. M., Aisen, P., Chen, C., Lleó, A., Iwatsubo, T., Iwata, A., Yamada, M., Ikeuchi, T., Jia, J., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12372 · Cited by 77
Mattke, S., Cho, S. K., Bittner, T., Hlávka, J., & Hanson, M. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12081 · Cited by 70
“tal State Examination [MMSE]), (2) BBBM test only, (3) MMSE followed by BBBM if”
MethodSelf-citationCurrent and evolving treatment strategies for the Alzheimer disease continuum
(2020) · The American Journal of Managed Care · doi:10.37765/ajmc.2020.88481 · Cited by 66
2026 Alzheimer's disease facts and figures
(2026) · Alzheimer s & Dementia · doi:10.1002/alz.71345 · Cited by 112
Expected wait times for access to a disease‐modifying Alzheimer's treatment in the United States
Mattke, S., & Hanson, M. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12470 · Cited by 72
“It assumed that (2) only patientswith actual cognitive declinewould seek out evaluation rather than the cognitively normal but worried, and that (3) individuals who tested negative at any stage of the pathwaywould not return for a subsequent evaluation.”
BackgroundSelf-citationThe costs of dementia subtypes to California Medicare fee‐for‐service, 2015
Chen, Y., Wilson, L., Kornak, J., Dudley, R. A., Merrilees, J. J., Bonasera, S. J., Byrne, C., Lee, K. P., Chiong, W., Miller, B. L., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.03.015 · Cited by 68
“This gap in care, which been attributed to the limited capacity of dementia specialists [30], creates missed opportunities for appropriate treatment and management [8].”
BackgroundGreen, C., Handels, R. L. H., Gustavsson, A., Wimo, A. B., Winblad, B. G., Sköldunger, A., & Jönsson, L. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.05.004 · Cited by 64
Koenig, L. N., Day, G. S., Salter, A. R., Keefe, S., Marple, L. M., Long, J. M., LaMontagne, P., Massoumzadeh, P., Snider, B. J., Kanthamneni, M., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102248 · Cited by 70
“Their value is expected to further increase as ADmodifying therapies are realized, creating a need and rationale for population-level screening and an influx of patients requiring timely diagnosis and treatment (Liu et al., 2017).”
BackgroundLessons Learned from Approval of Aducanumab for Alzheimer's Disease
Heidebrink, J. L., & Paulson, H. L. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-051022-043645 · Cited by 70
“In a simulation analysis of US preparedness to provide a therapy such as aducanumab, the availability of dementia specialists was identified as the most pressing constraint (56).”
Hampel, H. J., Vergallo, A., Iwatsubo, T., Cho, M., Kurokawa, K., Wang, H., Kurzman, H. R., & Chen, C. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12655 · Cited by 66
Alzheimer's disease diagnosis and management: Perspectives from around the world
Kerwin, D., Abdelnour, C., Caramelli, P., Ogunniyi, A., Shi, J., Zetterberg, H., & Traber, M. (2022) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12334 · Cited by 49
Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management
Galvin, J. E., Aisen, P., Langbaum, J. B., Rodriguez, E., Sabbagh, M., Stefanacci, R., Stern, R. A., Vassey, E. A., de Wilde, A., West, N., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2020.592302 · Cited by 56
“If such a therapy becomes available, one of the largest constraints to its use is projected to be the limited availability of specialists to evaluate and diagnose patients (14).”
BackgroundInfluentialA multimodal machine learning model for predicting dementia conversion in Alzheimer’s disease
Lee, M., Kim, H. W., Choe, Y. S., Yang, H. S., Lee, J., Lee, H., Yong, J. H., Kim, D., Lee, M., Kang, D. W., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-60134-2 · Cited by 62
Estimated Annual Spending on Lecanemab and Its Ancillary Costs in the US Medicare Program
Arbanas, J. C., Damberg, C. L., Leng, M., Harawa, N. T., Sarkisian, C. A., Landon, B. E., & Mafi, J. N. (2023) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.1749 · Cited by 47
Viscoelastic Properties of Human Autopsy Brain Tissues as Biomarkers for Alzheimer's Diseases
Park, K., Lonsberry, G. E., Gearing, M., Levey, A. I., & Desai, J. P. (2018) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2018.2878555 · Cited by 47
Prados, M. J., Liu, Y., Jun, H., Lam, J., & Mattke, S. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12578 · Cited by 42
Self-citationIoT-Based Unobtrusive Physical Activity Monitoring System for Predicting Dementia
Kim, J., Cheon, S.-H., & Lim, J. (2022) · IEEE Access · doi:10.1109/access.2022.3156607 · Cited by 41
“Dementia is a general term for progressive impairment of memory, language, problem-solving and other thinking abilities, severe enough to interfere with daily life and requiring considerable care [1].”
BackgroundA Transfer Learning Approach: Early Prediction of Alzheimer’s Disease on US Healthy Aging Dataset
Reddy, C. K. K., Rangarajan, A., Rangarajan, D., Shuaib, M., Jeribi, F., & Alam, S. (2024) · Mathematics · doi:10.3390/math12142204 · Cited by 36
Possible Consequences of the Approval of a Disease-Modifying Therapy for Alzheimer Disease
Musiek, E. S., & Morris, J. C. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.4478 · Cited by 35
Roth, S., Burnie, N., Suridjan, I., Yan, J. T., & Carboni, M. (2023) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr230007 · Cited by 37
“An earlier analysis found the US healthcare system to have capacity constraints, mainly in terms of insufficient specialists, but also in terms of access to imaging and to infusion centers [57].”
BackgroundA blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment
Monane, M., Johnson, K. G., Snider, B. J., Turner, R. S., Drake, J. D., Maraganore, D. M., Bicksel, J. L., Jacobs, D. H., Ortega, J. L., Henderson, J., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51863 · Cited by 32
“Third, such a test should be able to rule out and rule in brain amyloid and influence clinical decision making around diagnosis as well as management strategies.(1,19,20) As observed in this study, the PrecivityAD blood test and the APS result showed evidence of all these key features.”
BackgroundWhat older adults do with the results of dementia screening programs
Galvin, J. E., Tolea, M. I., & Chrisphonte, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235534 · Cited by 32
Liu, J., Hlávka, J. P., Coulter, D., Baxi, S. M., Mattke, S., & Gidengil, C. A. (2019) · RAND Corporation eBooks · doi:10.7249/rr2744 · Cited by 32
Self-citationGeographic variation in shortfalls of dementia specialists in the United States
Liu, J., Baker, L., Chen, A. Y.-A., & Wang, J. (2024) · Health Affairs Scholar · doi:10.1093/haschl/qxae088 · Cited by 30
“14,15 Access to care is likely to be unequal across the United States as estimated neur-ologist and geriatrician shortfalls vary by state.”
BackgroundSelf-citationIndependent study demonstrates amyloid probability score accurately indicates amyloid pathology
Fogelman, I., West, T., Braunstein, J. B., Verghese, P. B., Kirmess, K. M., Meyer, M. R., Contois, J. H., Shobin, E., Ferber, K. L., Gagnon, J., et al. (2023) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51763 · Cited by 25
Lam, J., Hlávka, J. P., & Mattke, S. (2019) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2019.06.180328 · Cited by 24
“A recent study has shown that the US health care system is ill prepared to meet this demand because of a lack of specialists and diagnostic and treatment centers.(3) Estimated wait times of up to 19 months could potentially lead to around 2.”
BackgroundSelf-citationAshford, M. T., Veitch, D. P., Neuhaus, J. M., Nosheny, R. L., Tosun, D., & Weiner, M. W. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12253 · Cited by 23
Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
Ketchum, F. B., Chin, N. A., Grill, J. D., Gleason, C. E., Erickson, C. M., Clark, L. R., Paulsen, J. S., & Kind, A. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12620 · Cited by 21
Stimmel, M. B., Orkaby, A. R., Ayers, E. I., Verghese, J., Nsubayi, C. K., & Weiss, E. F. (2024) · Journal of the American Geriatrics Society · doi:10.1111/jgs.18705 · Cited by 22
Logroscino, G., Urso, D., Gnoni, V., Giugno, A., Vilella, D., Castri, A. D., Barone, R. M. E., Nigro, S. L., Zecca, C., Blasi, R. D., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16534 · Cited by 23
“Notwithstanding the large and structural differences in the two health systems, a similar proportion of DMT candidates have been reported by this group in the United States [ 12].”
Rao, S. M., Galioto, R., Sokolowski, M., Pierce, M., Penn, L., Sturtevant, A., Skugor, B., Anstead, B., Leverenz, J. B., Schindler, D., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220929 · Cited by 18
“Finally, a 2017 RAND Corporation report [5] indicated that the US health-care system is unprepared to cope if a disease-modifying drug is approved, with a major constraint being the limited capacity to identify MCI and early-stage AD patients.”
BackgroundPractical algorithms for amyloid β probability in subjective or mild cognitive impairment
Maserejian, N. N., Bian, S., Wang, W., Jaeger, J., Syrjanen, J. A., Aakre, J. A., Jack, C. R., Mielke, M. M., & Gao, F. (2019) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.09.001 · Cited by 18
“the US, with a health care system ill equipped for confirming pathology in this large population, and similar problems in other countries [8,9].”
BackgroundMethodInfluentialNovel techniques for early diagnosis and monitoring of Alzheimer’s disease
Parul, P., Singh, A. K., & Shukla, S. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2415985 · Cited by 17
“The present panel of tests that physicians can employ as a component of the multiphase diagnostic procedure is being expanded through ongoing research [113].”
Lam, J., Jun, H., Cho, S. K., Hanson, M., & Mattke, S. (2021) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12159 · Cited by 15
Self-citationPractical Considerations in the Administration of Aducanumab for the Neurologist
Coerver, K. A., Yu, M. M., D’Abreu, A., Wasserman, M., & Nair, K. V. (2021) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000001144 · Cited by 11
“Similarly, the increased demands on diagnostic Aβ PET imaging and MRIbased surveillance monitoring may further burden imaging facilities.(29) For private practices entering into the world of infusible therapies for the first time, consideration of how insurers reimburse infusible therapies, which infusion sites are co…”
BackgroundHazan, J., Liu, K. Y., Fox, N. C., & Howard, R. J. (2023) · Brain Communications · doi:10.1093/braincomms/fcad322 · Cited by 10
Clevenger, C. K., Lingler, J. H., Zhang, Y., Assunção, S. S., Parnas, M. L., & Youmans-Kidder, K. (2024) · Geriatric Nursing · doi:10.1016/j.gerinurse.2024.11.020 · Cited by 9
Choi, S. H., Kim, S., Ong, P. A., Chin, A., Dominguez, J. C., Chen, C., Senanarong, V., Hu, C. J., Tripathi, M., Mok, V., et al. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2025.100215 · Cited by 9
“Addressing capacity constraints was deemed challenging as it required solving a labyrinth of issues regarding payment policy, regulatory requirements, workforce considerations, and capacity planning at national and local levels, combined with awareness campaigns [ 21 ].”
Memory Care Approaches to Better Leverage Capacity of Dementia Specialists: A Narrative Synthesis
Lam, J., & Mattke, S. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0038 · Cited by 9
Self-citationPotashman, M. H., Parcher, B., Zhou, J., Hou, Q., & Stefanacci, R. G. (2022) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2045956 · Cited by 8
Predicting amyloid‐beta pathology in the general population
Ho, P. T. N., van Arendonk, J., Steketee, R. M. E., van Rooij, F. J. A., Roshchupkin, G. V., Ikram, M. A., Vernooij, M. W., & Neitzel, J. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13161 · Cited by 7
“46 The current study has several limitations.”
Jun, H., Cho, S. K., Aliyev, E. R., Mattke, S., & Suen, S. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201203121907 · Cited by 7
Self-citationGiaquinto, F., Lorenzini, P., Salvi, E., Carnevale, G., Vaccaro, R., Matascioli, F., Corbo, M., Locuratolo, N., Vanacore, N., Bacigalupo, I., et al. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240594 · Cited by 6
Weber, M., Roth, H. L., Abramowitz, A., & Johnson, K. G. (2025) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2025.02.007 · Cited by 6
“27 As antiamyloid therapies become more widely available, increased access to clinical evaluations at early stages of cognitive decline is a requirement.”
Rational Design of a Cu Chelator That Mitigates Cu‐Induced ROS Production by Amyloid Beta
Mitra, S., Talukdar, K., Prasad, P., Misra, S. K., Khan, S. I., Sharp, J. S., Jurss, J. W., & Chakraborty, S. (2021) · ChemBioChem · doi:10.1002/cbic.202100485 · Cited by 6
The Role of Clinical Trials in Preclinical Alzheimer's Disease Drug Development Programs
Cummings, J. L. (2020) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.28 · Cited by 5
“Recent surveys of the ability to respond to the approval of new treatments for prodromal AD show that there are too few clinicians skilled in diagnosis, too few PET facilities to establish the amyloid status, and too few infusion centers to treat all treatment candidates if the therapy is administered intravenously (1…”
BackgroundVassilaki, M. E., Aakre, J. A., Lesnick, T. G., Kremers, W. K., Graff‐Radford, J., Knopman, D. S., Mosley, T. H., Windham, B. G., Griswold, M. E., Geda, Y. E., et al. (2025) · AJPM Focus · doi:10.1016/j.focus.2025.100324 · Cited by 5
Evolution of Detecting Early Onset of Alzheimer’s Disease: From Neuroimaging to Optical Immunoassays
Hsiao, W. W., Angela, S., Le, T., Ku, C., Hu, P., & Chiang, W. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221202 · Cited by 5
“According to the RAND Corporation, using CSF biomarkers as an alternative or in conjunction with amyloid PET may lessen the wait times for amyloid treatment in several countries, i.e., Japan [101], the US [102], Europe [103], and Canada [104].”
Khachaturian, A. S., Cassin, B., & Finney, G. R. (2023) · Journal of Aging Research and Lifestyle · doi:10.14283/jarlife.2023.3 · Cited by 4
Song, G., Wu, H., Chen, H., Zhang, S., Hu, Q., Lai, H., Fuller, C., Yang, G., & Chi, H. (2024) · Current Alzheimer Research · doi:10.2174/0115672050314171240527064514 · Cited by 4
Mattingly, T. J., McQueen, R. B., & Lin, P. (2021) · PharmacoEconomics · doi:10.1007/s40273-021-01079-6 · Cited by 4
Hlávka, J. P., Lavelle, T. A., Neumann, P. J., & Lin, P. (2022) · PharmacoEconomics · doi:10.1007/s40273-022-01150-w · Cited by 4
“There are millions of individuals with cognitive impairment in the USA who may seek out specialists to assess their eligibility for new AD disease-modifying drugs, and the capacity of specialists could be dwarfed by the demand [15].”
BackgroundCT-Detected MTA Score Related to Disability and Behavior in Older People with Cognitive Impairment
Lauriola, M., D’Onofrio, G., la Torre, A., Ciccone, F., Germano, C., Cascavilla, L., & Greco, A. (2022) · Biomedicines · doi:10.3390/biomedicines10061381 · Cited by 4
“Important biomarker information can be gleaned from imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and positive emission tomography (PET) that visualize early structural and molecular changes in the brain [7,8].”
BackgroundRini, J. F., Tsoy, E., Peet, B. T., Best, J., Tanner, J. A., Asken, B. M., Sanchez, A., Apple, A. C., VandeVrede, L. A., Stephens, M. L., et al. (2022) · Neurology Clinical Practice · doi:10.1212/cpj.0000000000200099 · Cited by 4
“These challenges are further exacerbated by a chronic shortage of dementia care specialists.(2-4) Individuals living with dementia often face a complex myriad of behavioral problems whose nuanced management is often beyond the capacity of their primary care providers.”
Background(2024) · doi:10.7249/rra2643-1 · Cited by 3
Self-citationChen, J., Lin, B., Seow, E., Kim, S., Bajaj, P. S., & Mattke, S. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251372129 · Cited by 3
Self-citationBiomarkers for Alzheimer's Disease – An Overview
Tyagi, U., Tripathy, D. B., Gupta, A., Bisht, K., & Nain, A. (2024) · Macromolecular Symposia · doi:10.1002/masy.202200218 · Cited by 3
“This has been modeled by the RAND Corporation for a number of nations, including the US, [36] Canada, [37] various EU member states, [38] and Japan.”
Associations of Plasma p‐tau181 With Age, Adjusted for Kidney Function and Sociodemographic Factors
Hazan, J., Liu, K. Y., Zetterberg, H., Fox, N. C., Howard, R. J., & with, A. D. N. I. (2025) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.70138 · Cited by 2
“Confirming AD biological status will be essential for both participant trial inclusion and selection of AD patients to receive disease‐ modifying treatments [14].”
Baxi, S. M., Girosi, F., & Liu, J. (2019) · RAND Corporation eBooks · doi:10.7249/rr2891 · Cited by 3
Self-citationAlzheimer’s Centers in US Hospitals: Enough to Adequately Address Dementia Care Nationwide?
Gutiérrez, Á., Cronin, C. E., Franz, B. A., & Terrera, G. M. (2023) · Journal of Aging and Health · doi:10.1177/08982643231200691 · Cited by 2
Wimo, A. B. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2021.1848551 · Cited by 2
Hanson, M., Liu, Y., Ozawa, T., Yin, H., & Mattke, S. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251385118 · Cited by 1
“8,9 Our study contributes to growing understanding of Americans who travel great distances for health care, including the 44.1% of Medicare bene fi ciaries who traveled more than 60 min to obtain surgical care in 2020, 21 and the 5% of rural Americans who live more than 150 miles from specialized…”
InfluentialSelf-citationRoth, S., Yan, J. T., Patru, M.-M., Mattke, S., Gustavsson, A., & Ortsäter, G. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877251406909 · Cited by 1
“11,12,34,35,37,38 All of these previous studies argue that these constraints need to be addressed or circumvented in order to deliver DMTs to people with early stages of symptomatic AD in a timely fashion.”
InfluentialSelf-citationReimagining Care Delivery for Alzheimer Disease
Burns, J. M., Woodward, J. L., Morris, J. K., & Townley, R. A. (2026) · JAMA Neurology · doi:10.1001/jamaneurol.2026.0801 · Cited by 1
Mattke, S., Chen, J., Hanson, M. S., Johnson, K. G., Leahy, C., Merrill, D. A., Shada, V., & Ruiz, J. G. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261467345 · Cited by 1
“In the same year, a modeling study predicted substantial wait times, particularly for appointments with memory specialists in the United States (US) 5 and later in other countries.”
Self-citationSupervised machine learning in psychiatry: towards application in clinical practice
Grassi, M. (2022) · Research Publications (Maastricht University) · doi:10.26481/dis.20220919mg · Cited by 1
Sen, S. E. (2025) · medRxiv · doi:10.64898/2025.12.30.25343198 · Cited by 1
Revolutionizing Alzheimer’s Diagnostics: AI Tool Shows Superior Accuracy over Traditional Methods
Svanishvili, G. (2024) · Premier Journal of Neuroscience · doi:10.70389/pjn.100004 · Cited by 1
Mattke, S., Yoong, J., Yuen, K., & Loh, W. K. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5163833
Self-citationJoe, E., & Segal‐Gidan, F. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02770-9
“…significant undersupply of dementia care specialists (including neurologists, psychiatrists, and geriatricians) to support primary care clinicians [3, 4], a problem that can be especially challenging in health systems that serve vulnerable populations, such as those who are low-income and have…”
Sideman, A. B., Alagappan, C., Arteaga, I., Breithaupt, A. G., Soleymani, S., Belani, H., Pham, T., Pak, S., Sigala, T., Gravano, J. T., et al. (2026) · BMC Family Practice · doi:10.1186/s12875-026-03437-9
Treatment of Alzheimer’s Disease
Cummings, J. L. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108985055.021
Tsoy, E., & Possin, K. L. (2025) · Cambridge University Press eBooks · doi:10.1017/9781108985055.002
Beyond the Cochrane review: Re‐evaluating anti‐amyloid therapy in Alzheimer's disease
Bernath, M. M., Brosch, J. R., Saykin, A. J., Wilcock, D. M., Summanwar, D., & Willis, D. R. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71769
“21 The recent emergence of subcutaneous lecanemab could reduce health system burden and add time savings and convenience for patients.”
Metadata
- Authors
- Liu, J., Hlavka, J., Hillestad, R., & Mattke, S.
- Venue
- RAND Corporation eBooks
- Publisher
- RAND Corporation
- Published
- 2017
- OpenAlex
- W2770679810
- Cited by
- 98
- References
- 9
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 13 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 10 · 2019: 10 · 2018: 4 · 2017: 1
- FWCI
- 11.87
- Type
- book
- Language
- en
- Open access
- closed
- Locations
- RAND Corporation eBooks (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Keywords
- Alzheimer's disease, health system preparedness, health infrastructure, early Alzheimer's disease, dementia prevention, screening and diagnosis, health care capacity, health policy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.